Protara

Protara (formerly Proteon) is developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company’s lead product, a recombinant human elastase, is in late-stage trials to prolong the patency and reduce the failure of haemodialysis vascular access in patients with chronic kidney disease. The company went public in October 2014.